Financial research concept

Accelerated Approval: FDA Pathway Based on Surrogate or Intermediate Endpoints

Accelerated approval can allow earlier FDA approval for serious conditions based on a surrogate or intermediate endpoint reasonably likely to predict clinical benefit.

By Lee BaileyPublished Sep 21, 2026

Research context

See what supports this page, how current it is, and where comparable or historical context is available.

Research date: Sep 21, 2026Use the dated article and cited sources for the definition, examples, and stated limitations.
Operating-model context: 16 connected conceptsPart of the reviewed Biopharma Development and Commercialization; issuer definitions remain distinct where disclosed.

Why investors care
What to check
Part of the Biopharma Development and Commercialization
See It in Company Research
Continue Research

Accelerated approval is an FDA pathway that can allow earlier approval of drugs for serious conditions based on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit.

Why investors care

Accelerated approval can shorten the path to market, but it can also create important post-approval obligations.

FDA can require confirmatory studies to verify anticipated clinical benefit. Failure to confirm benefit can lead to regulatory action, including procedures that may remove the indication from the market.

What to check

Investors should distinguish:

accelerated approval from traditional approval;
the surrogate or intermediate endpoint used;
confirmatory-study requirements;
timing of those studies; and
whether clinical benefit has later been verified.

Source:

FDA Accelerated Approval Program

Accelerated approval changes the evidentiary path to approval. It does not eliminate the need to confirm clinical benefit.

Part of the Biopharma Development and Commercialization

Connect clinical-trial evidence, FDA application and expedited pathways, collaboration economics, gross-to-net commercialization, and loss-of-exclusivity risk to understand drug-development businesses.

Browse the full operating model in Company Analysis →

Where this concept fits

FDA pathway and review milestonesCurrent relationship
NDA and BLA submissions begin formal marketing review for drugs and biologics, PDUFA dates frame target action timing, and accelerated approval, Breakthrough Therapy, and Orphan Drug designations describe distinct regulatory pathways or incentives rather than approval outcomes.
Accelerated ApprovalCurrent conceptBiologics License Application Breakthrough Therapy Designation New Drug Application Orphan Drug Designation PDUFA Date
Clinical evidence and execution
Trial phase frames development maturity, enrollment affects execution timing, primary and secondary endpoints define the prespecified evidence hierarchy, and a readout converts that study design into new evidence for investors to interpret.
Clinical Trial Phase Clinical Trial Readout Patient Enrollment Primary Endpoint Secondary Endpoint
Commercialization, partnerships, and exclusivity
Gross-to-net adjustments bridge gross product demand to recognized revenue, royalties and milestones describe partner economics, and patent expiry plus loss of exclusivity frame when legal protection may translate into competitive revenue erosion.
Biopharma Gross-to-Net Adjustment Biopharma Milestone Payments Biopharma Royalty Revenue Loss of Exclusivity Biopharma Patent Expiry

See It in Company Research

Explore other companies in this operating model

These companies are linked to at least two other reviewed concepts in the same operating model, but are not currently linked to this concept. This is broader research navigation, not evidence that the company reports an equivalent metric.

Continue Research

Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.

Compare stocks

Compare biopharma stocks

Continue into stock comparison for pipeline stage, regulatory milestones, commercialization economics, concentration, and valuation context.

Continue research

Explore more topics in the Financial Research Encyclopedia.